1

Max India Limited

Investor PresentationJuly 2009

BSE Scrip Code: 500271, NSE Ticker: MAX, Bloomberg: MAX:INwww.maxindia.com

2

VISION“To be one of India’s most admired corporates for service excellence”

Max India – An Introduction

Life Insurance

Protecting Life

HealthcareCaring for Life

Clinical Research

Improving Life

Health Insurance*

Enhances Life

* JV agreement signed on September 3, 2008. Statutory approvals in process.

Multi-business corporate I Focused on people and service

“ IN THE BUSINESS OF LIFE ”

3

Our Other Business

ManufacturingNiche high barrier polymer films & Leather Finishing Foils.

Focus on healthcare, children and the environment.

Corporate Social Responsibility

Max India – An Introduction

4

Max India Group – Key Highlightsn A leading conglomerate of repute in India

Life Insurance – 74:26 JV with New York Life

Healthcare – 70% owned. 8 healthcare facilities with around 800 Beds

Clinical Research – 100% owned. 175+ active sites

Speciality Packaging – capacity of 29,000 TPA. 100% utilization

Health Insurance – JV with BUPA Finance Plc, UK

n 3.5 Million Customers… 20,000 Employees… 84,000 Agents… 1,200 Doctors…

n Track record of successful international business partnerships over last 20 years

Pharmaceuticals Electronic Component

Mobile Telephony

CommunicationServices Plating Chemicals Medical

Transcription

Hutchison COMSAT ATOTECH

5

Consolidated Financial Snapshot(Rs. Crore)

1,111

1,994

3,611

4,891

* Losses have increased on account of significant expansion undertaken in the life insurance business.

Details FY09 FY08Gwth.

(%)

Operating Revenue 4,508 3,244 39%

Investment and Other Income 383 367 4%

Total Revenue 4,891 3,611 35%

Profit/(Loss) After Tax* (333) (60) -

Net Worth 1,312 1,537 -15%

Preference Shares 250 250 -

Loans Funds 347 552 -37%

Fixed Assets (Net Block) 930 718 30%

Treasury Corpus 413 1,261 -67%

Life Insurance Investments (AUM) 5,405 3,575 51%

6

FDI –Warburg Pincus12.8%

Max India – Shareholding

FII – Warburg Pincus8.7%

FII – Others24.8%

Others16.0%

Number of Outstanding Shares – 232,356,621

Promoter Group –Analjit Singh

33.3%

As on Jun 30, 2009

FDI – IFC4.4%

7

n Joint-venture with BUPA Finance Plc., UK, world leader of highest

pedigree in this space

n Management team in place

n Currently in the process of seeking regulatory approvals

n Initial capital of Rs. 100 Crore to be infused

Max India to foray into Health Insurance…

8

Max New York Life Insurance [ MNYL ]

www.maxnewyorklife.com

9

n Joint Venture between Max India and New York Life, a fortune 100 company witharound $280 billion in assets under management

n Max India and NYL jointly drive growth strategy

n Max provides Indian industry perspective and manages the regulatory environment

n Capital Investment of Rs. 1,782 Crore

Max New York Life Insurance [ MNYL ]

10

India’s Life Insurance Industry has shown strong growth till FY08

Growth driven by…n Strong GDP growth (Average of 8.9% since last four years)

n Low Life insurance penetration (4.6% of GDP as against world average of 7.5%)

n Aggressive distribution expansion by private players (Over 6000 new offices in 4 years)

n Favorable demographics (working population, aged 15-64 yrs, is over 60%)

n Product Innovation (Unit Linked products, Health & Pension)

Individual Adjusted Premium (Individual Non-Single Premium + 10% of Individual Single Premium)Source: IRDA website

11

Industry growth rate moderated in FY09

Source: IRDA website

Pvt. Players 1%

MNYL 22%

LIC -22%

MNYL improved its market share to 6% in FY09 from 5% in FY08

12

Market PositionInsurance Sales (Rs. Crore)

Source: Insurance Regulatory & Development Authority, Adjusted to include only 10% of Single PremiumAll Others include: Kotak, Aviva, Met Life, Shriram, Bharti AXA, Sahara, IDBI Fortis, Future Generali, Canara HSBC OBC, Aegon Religare, DLF Pramerica

and Star Union Dai-ichi

CompanyIndividual New Business

PremiumIndividual Policies

ICICI Prudential 5,146 2,638

Bajaj Allianz

2,892 937

HDFC Standard Life

1,595 1,207Max New York Life

2,443 1,383

Canara HSBC OBCING Life

3,777 2,590Reliance Life

3,849

36

All Others

292

1,867Total Private Life Insurers 26,876 15,007

MS of Private Players (%) 57 29

5

2,310 1,074

SBI Life

958 698

7

Tata AIG

358637

(FY 2008-09)

285282243

184

237

329

76

2,231

50

198

108

3

72

(Apr-May’09)(‘000)

(FY 2008-09)

22694

156

198

204

8

1601494

31

5

82

92

41

2,977 2,219

Birla Sunlife

217 233

(Apr-May’09)

13

n Multi-channel distribution strategyHighly productive agency model (Over double the average productivity ofprivate players)Strong non-agency relationships contributing to over 35% of sales in FY 08-09

n Comprehensive product suite across all market segmentsStrong traditional products portfolioComprehensive Unit Link product suiteRecently launched Health and Retirement products

n Best in class training capabilities (over 850 trainers on board)Advise based insurance sales by AgencyDetailed need analysis

n Long tenor products and young customer base

n Conservation ratio* of 82% in FY 08-09… amongst best in industry

n Scalability of IT and administration systems

n Strong management team with proven execution capabilities

MNYL Key Differentiators

* Conservation ratio is defined as Current Period Renewal premium / (Last Period Renewal Premium + Last Period Regular Business Premium)

14

n Golden Peacock Innovation Award 2008 for Max Vijayn Grant of US$ 400K from International Labour Organization (ILO) for Max Vijayn 7th best company to work for in India by Mercer Business Today Surveyn CIO 100 Award for innovation in technology implementationn CII Business Excellence commendation for “Strong Commitment to Excel”n Selected to the Elite group of ‘Super Brands’ in India for

branding effortsn Ranked 2nd in BT-Cirrus Newsmakers Survey of most written about private life

insurance company in the median Featured in Top 50 Best Companies to Work for – 2009 by ‘Great Place to

Work’n Outlook Money ranked MNYL # 1 in Slow, Medium and Quick fund category

MNYL – Rewards & Recognition

15

MNYL – The Leading Agency Sales Force

Source: IRDA Journal, media reports and company’s internal estimates

Adjusted Single premium

719 78,000 9,173 0.67

3,293 290,000 9,204 0.47

1,591 80,000 21,974 0.71

427 50,000 8,203 0.25

1,786 149,613 8,919 0.66

478 60,000 7,062 0.40

1,588 166,000 9,623 0.54

1,271 207,000 6,021 0.28

295 38,000 6,712 0.38

•In terms of highest new business premium (Agency)** Average agents

648 45,000 13,545 0.57

1,053 78,827 15,232 1.04

2,455 250,000 8,180 0.56

2

1

6

7

3

9

4

510

11

12

8

1

2

3

4

5

6

7

89

10

11

12

New Business FY 2008-09

(Agency) (Rs. Crore)Agents** Premium per

Agent * (Rs.)Cases per Agent *Rank Rank

16

MNYL Focus… Protection Oriented, Longer Tenor Life Insurance

34

28

33

1DEFERRED ANNUITY

8MONEY BACK

UNIT LINKED 54

3TERM

18WHOLE LIFE

PROPORTION OF POLICIES (%, by

number)

PRODUCT TYPETenure (Years)

Age of Insured(Years)

21 34MNYL Average MNYL Average

15

24

43

34

3616

14

42

ENDOWMENT 12 22

As on Mar 31, 2009

HEALTH 4 3613

17

Other Operating Variance

MNYL – Embedded Value 2008-09

Amount in Rs. Crore

Unwind of discount

Opening EV

Value ofNew

BusinessNew Capital

Injection

Closing EV

Denotes decrease to EV

Denotes increase to EV

312

190

Market Value

Movement

44750

9

2,284

CostOverrun

392

Implied NBM is 21.0% on APE*

(21.8% in 2007-08)

954

362

767

1,517

Net Worth

Value of Inforce business

1,316

Other Adjustments

55

*APE – Annualized First Year Premium adjusted for 10% of Single Premium and 50% of limited pay products

18

Economic Assumptions

Sensitivityn For change in risk discount rate by 0.5%, the value of new business would change

by 4.9%

Operating Assumptionsn Operating assumptions like mortality, morbidity and lapses are based on our own

experience and validated with industry / reinsurers experience.

n Expense assumptions are based on our own expense projection model. Basis ourcurrent expansion strategy, our expense break even happens in year FY 11-12

MNYL – Key Assumptions to Embedded Value

Particulars AssumptionsCash/Money Market/TB 5.50%G Secs 7.00%Corporate Bonds 8.50%Equities 13.00%Inflation 5.00%Risk Discount Rate 13.00%Tax rate 14.2% (12.5% plus 10% surcharge

+3% education cess)

19

MNYL – Growth Strategy

*Growth rate calculated on Individual Adjusted Premium(Individual Non-Single Premium + 10% of Individual Single Premium)

20

n MNYL would continue to be an agency led multi-channel distribution company. Keyfocus areas in distribution would be:

Grow agency and rural offices to build large geographic footprintSegment agency to build profitable scaleStrengthen and expand bancassurance and partnership distributionBuild scale in direct sales and exploit telemarketing capabilities

n Launch a new operating model to reach 100 millionlow income, under-serviced households, through

Successful Pilot done in Allahabad and Andhra PradeshActivated 30+ retail distributors in UPMajor tie up done with 2 MFI & 2 NGOsReady to establish 50,000 Point Of Sales by year endInitiated business partnerships with large format retailers including Reliance Retail, 3iInfoTech, Tata Capital to leverage their existing customers and POS relationships.Peerless signed up to distribute Max Vijay – encouraging early results

n Focus on health and retirement product segments to diversify the portfolio and fuelgrowth

n Enhance sales through cross-sell and up-sell to our growing customer base

n Improve MNYL brand awareness to support business expansion throughcomprehensive brand building agenda

MNYL – Growth Strategy

21

www.maxhealthcare.in

Max Healthcare [ MHC ]

22

Indian Healthcare

Indian Healthcare industry expected to grow at a 15%

CAGR till 2012 to contribute 6.1% of GDP

Key Driversn Key changes related to lifestyle and chronic

disease patternsn Minimally Invasive Surgery, lower ALOS & safer

surgical procedures – encouraging demandn Deeper penetration of diagnostics and

healthcare servicesn Growing middle classn Changing spending patternsn Health Insurancen Medical value travel

Healthcare Industry 2012 – US$ 78.6 billion

n Revenue generated by private hospitalscurrently estimated at US$ 15.5 billion, likely toincrease to US$ 35.9 billion by 2012

n Industry expected to add 1 million beds by 2012– private sector to contribute 89% of these bedsat an investment of US$ 70 billion

Source: FICCI & E&Y Report, 2007

Healthcare Industry 2012 - US$ 78.6 Bn

Bed Revenue, 36%

Health Insurance, 5%

Infrastructure, 14%

Others, 18%

Training & Education, 3%

Pharma and Consumables,

21%

Clinical Trials, 1%

Medical Value Travel, 2%

23

Enable retention of patient trafficEnable ‘start-to-finish’ comprehensive, seamless care: Consult and Diagnostics,

Diagnostic tests, surgeries, post-surgical care

MHC – Model

TERTIARYn Max Heart and Vascular Instituten Max Super Speciality Hospital

Heart and VascularNeurosciencesJoint Replacement and OrthopaedicsAesthetics and Reconstructive surgeryOncology

SECONDARY

PRIMARY

n Max Hospitals – 4n Speciality Centres – 2

n Clinics / Implants – 10

Surgery and inpatient facilitiesMother and ChildHigh-end diagnostics: MRI, CTDoctor consultationEye and Dental care

Specialist doctor consultBasic diagnostics like pathology collection

24

n Comprehensive world-class healthcare services

n State-of-the-art infrastructure and facilities

n Established brand name with leading specialist doctors

n Trained and anchored resources

n Leadership in key super-specialties in tertiary careCentres of excellence in cardiac, orthopaedics and joint replacement, neurosciences,paediatrics, obstetrics & gynaecology and aesthetic & reconstructive surgery

Organ transplant, oncology, cord blood banking, stem cell research to be added

n Extensive emphasis on medical training and educationDNB (Diplomate of National Board) & fellowship programs

High quality nursing and paramedic care supported by nursing and paramedic college

MHC – Key Differentiators

25

Healthcare facilities 8

Physicians 1,200*

Other support staff 3,100

Patient base Around 750,000

Patient transactions Over 160,000 pm

Beds Around 800

ICU beds 230

OTs 20

Cathlabs 3

MRIs 4

CTs 4

MHC – Key Highlights

*Includes over 500 physicians on Rolls

Fact Sheet Shareholding Pattern

Max India Limited70.1%

Others6.0% Warburg Pincus

20.1%IFC, Washington3.8%

Number of outstanding shares 237,094,548

Both the tertiary care hospitals are NABH accredited Lab facilities at Max Super Speciality Hospital are NABL accredited

26

MHC – Key Highlights

The business has turned Cash Positive …

*Average revenue per occupied bed day has been calculated on inpatient revenue

ALOS – 3.3 days

27

MHC – Second Phase of Expansion

Max Balaji Hospital – Patparganj

Max Hospital – Shalimar Bagh

Max Hospital – South Block , Saket

Max Hospital – Dehradunn Tertiary Care facility

n Around 260 beds

n Launch expected by October 2009

n Tower specialities include – Oncology, Cardiac Care, Orthopaedics, Neurosciences and Critical care

n Multispecialty services

n Around 300 beds

n First phase Launch expected by April 2011

n Tower specialities -Interventional Cardiology, Cardio thoracic surgeries, Neurosciences, Trauma & critical care.

n Tertiary Care facility

n Around 90 beds

n Launch expected by April 2010

n Tower specialty - Oncology

n Multi-specialty services

n Around 150 beds

n Launch by April 2010

n Tower specialty includes - Emergency and Trauma care, Non-invasive and Invasive cardiology, Cardio-thoracic surgery, Joint replacement and Orthopaedics, Minimally Invasive Surgery, Neurosciences and related support services.

Max Hospital – Greater Noida

NCR Region Outside of NCR Region

Max Hospital – Mohali

n Tertiary Care facility

n Around 300 beds

n First phase Launch expected by April 2011

n Tower specialty includes – Oncology, Cardiac Services & Trauma Services

Max Hospital – Bathinda

n Tertiary Care facility

n Around 300 beds

n First phase Launch expected by April 2011.

n Tower specialty includes – Oncology, Cardiac Services.

n Multispecialty services

n Around 300 beds

n Launch expected by April 2012

n Tower specialities neurosciences, trauma and critical care, urology, interventional cardiology and cardio thoracic.

Land already in place for the Second Phase of expansion

28

MHC – Funding Structure

Project CostRs. 981Crore

EquityCapital

Rs. 376 Crore

PreferenceCapital

Rs. 250 Crore

n Max IndiaCurrent – Rs. 166 Crore

n Warburg Pincus – Rs. 140 Croren IFC, Washington – Rs. 50 Croren Other Foreign Investors – Rs. 20 Crore

n Indian Banks and FinancialInstitutions

Current – Rs. 297 CroreFuture (tied-up) – Rs. 58 Crore

Debt Funds

Rs. 355 Crore

n IFC, Washington

29

Max Neeman Medical International [ MNMI ]

www.neeman-medical.com

30

Revenue Mix - Clinical Trials

Phase-IV10%

Phase-III30%

Phase-II40% Phase-I

20%

Indian Clinical Research Industry

Key Driversn Huge patient population base

with therapeutic diversity

n Cost arbitrage

n Huge talent pool

n Data processing infrastructurefor bio-informatics

n Favorable patent regulationsto catalyze exponential growthand improvingNeed availability gap in years to come

Source: FICCI E&Y Report, 2007

Industry projected to grow to US$ 1.3 billion by 2012...

Indian clinical trials industry - US$ 200 million in 2006

31

MNMI – Contract Research Organization

n Service offerings include…Project managementMonitoringSite managementData management, includes bio-statistics and report writingClinical trial material supply chain management

n Confirmed order book of Rs. 40 CroreBD efforts focused on medium and small-sized biotech and pharma companies

n Strong operating performance…Continues to be profitableRevenue for the FY09 over Rs. 14 Crore, grows 29% year-on-year.Patient retention rate maintained at 98%4 successful US FDA auditsDatabase of over 800 GCP/ICH principal investigators

32

MNMI – Select List of Clients

33

Max Speciality Products [ MSP ]

www.maxindia.com

3434

Global BOPP IndustryKey Driversn Global flexible packaging industry – US$ 50

bn, of which BOPP Films contribute 70%

n Growth of flexible packaging Industry ~ 15%in India & 7 to 8% Globally

n Competitive advantage of BOPP films overother plastics and traditional products

n Shift from PET to BOPP. (Indian BOPP:PETproducts ratio around 1:2 against 3:1 globally)

n BOPP films in strong demand from consumergoods industries

n Organised retail and changing urban lifestyles to further expand demand for BOPPfilms

n Competitive cost advantage for exportmarkets

BOPP per capita consumption in India lower than

the global average

Source: AMI & Access

Global Per Capita Consumption of BOPP Film

1.9

1.2

0.50.4

0.30.1

0.4

WesternEurope

NorthAmerica

Asia LatinAmerica

EasternEurope

India WorldAverage

KG

35

Max Speciality Products is much more than packaging…n Manufacturer of niche (high margin) and high barrier speciality polymer films

n Pioneer in introduction of value added products / technology in India

n Long term relationship with blue chip customers

MSP – Key Differentiators

Commodity Speciality(Preferred)

End UsePackaging,Industrial,

Textiles

Packaging,Lamination

MetallisedFilms Coated Films Foils

Packaging,Lamination,Industrial,

Packaging, Industrial

Lifestyle,Apparels

Our Focus

36

MSP – Key Highlights

Track Record of Strong Performance…

n BOPP lines of 29,000 TPA running at 100% utilization

n Fourth BOPP line with capacity of 20,000 TPA, expected to be operational by 2010 end

n Return on Capital Employed for FY09 at 15%

n Third thermal line planned with a capacity of 10,000 KSM

n Leather finishing foil business to more than triple its capacity to 5000 KSM by Q2’FY10

37

Thank You

38

Max India – Management TeamMr. Analjit SinghChairman & Managing Director

Mr. Analjit Singh has been the driving force behind Max Group’s sustained growth and success since the early80’s. Mr. Singh a prominent industrialist is an alumnus of Doon School; University of Delhi, and the GraduateSchool of Management, Boston University

Mr. Anuroop (Tony) SinghVice Chairman

Mr. Anuropp (Tony) Singh was CEO & Managing Director of MNYL since its inception in 2000. In his previousassignments he worked as Country Head – India and Regional Head – Consumer Banking for ANZ GrindlaysBank; Country General Manager for retail banking at Bank of America and various senior positions with AmericanExpress

Mr. C. V. RaghuDirector – Legal & Regulatory

Mr. Raghu brings with him a rich and varied experience of 22 years, of which, 14 years have been spent withAmerican Express Bank. Prior to that, he has worked with Hindustan Lever Limited and CII. He holds a BachelorsDegree in Law from Faculty of Law, Delhi University.

Mr. Mohit TalwarDirector – Corporate Development

Mr. Talwar brings rich and varied experience of 28 years with The Oberoi hotels, Bank of Nova Scotia, Grindlays& Standard Chartered. In his last assignment with Standard Chartered he was responsible for developingstrategy, revenue & economic profit across products. Mr. Talwar is a post-graduate in Arts and HospitalityManagement.

Mr. P. DwarakanathDirector - Group Human Capital

Mr. Dwarakanath brings rich and varied experience of 37 years primarily from GSK GlaxoSmithKline ConsumerHealthcare and is currently the non Executive Director of GSK. He has done his Post Graduate diploma inPersonnel Management and Industrial Relations, B.Sc and Bachelor of Law.

Ms. Sujatha RatnamChief Financial Controller

Ms. Ratnam brings with her over 15 years of rich and varied experience with Jubilant Organosys and Tata Motorsand has expertise in the field of financial restructuring and fund raising. She is a Chartered Accountant.

Mr. V KrishnanCompany Secretary

Mr. V. Krishnan has more than 18 years of rich experience in Corporate Regulatory and Compliance matters andhas been closely involved in establishing joint ventures, mergers & acquisitions and business restructuring of MaxGroup. He is a member of the Institute of Company Secretaries of India.

39

MNYL – Management Team

Mr. Rajesh Sud –

Managing Director

and CEO

Mr. Sud, a founder member, has been instrumental in establishing MNYL’s distribution footprint across India. Today

MNYLs Agency model is recognized as “best-in-class”. Prior to joining MNYL, he was the CEO & Managing Director of

Esanda Finance Ltd (a financial services subsidiary of ANZ Grindlays Bank)

Mr. Rajit Mehta –

Chief Operating

Officer

Mr. Mehta, a founder member, has led and built the HR function of MNYL and provided overall HR direction in line with

business strategy. He has also played a significant role in managing change / transition agendas both at a functional

and organizational level while facilitating strategic initiatives. Prior to joining MNYL, he was Director - Human Resources

at Bank of America, India

Mr. John Poole

Chief Actuary

Mr. Poole, is both Chief Actuary and Appointed Actuary for MNYL. He has been instrumental in building MNYLs

actuarial capability and implementing best practices. Prior to this assignment, he worked with AMP in various key

management positions including CFO and Actuary

Mr. Sunil Kakar

Senior Director &

Chief Financial Officer

Mr. Kakar joined MNYL in March 2001 and is in charge of Finance, Accounts, Investments and Risk Management.

Under his leadership investment portfolio continues to generate top quartile returns. Prior to joining MNYL, Sunil was

with Bank of America, India as Vice President (CFO)

40

ExcellenceHonestyKnowledgeCaringIntegrityTeamwork

MNYL – Road Map to Becoming India’s Most Admired Life Insurance Company

Key Public Messages

A trusted life insurance specialistCustomer centricFinancially responsible and strongA great place to workAn admired member of the community

VISION Become the most admired Life Insurance Company in India

MISSION

KEY

OBJECTIVES

STRATEGIES

WHAT – Comprehensive suite of products, competitive pricing, extensive distribution, persistency, customer service excellence, profitable portfolios

HOW – Talented People, Professional & Productive Agents, Performance Metrics, Leverage Technology, Teamwork, Customer Centric, Innovative Distribution and Marketing

INITIATIVES What-When-Who-How-Cost linkage plans at Departmental and Individual levels

VALUES & BELIEFS OPERATING PRINCIPLES METRICS & STANDARDS

PERFORMANCE MGMT PROCESSCustomer comes first

International quality standardsDo it right the first timeFact based decisionsBias for result oriented actionFinancial strength & disciplineDirect and open communicationRespect Max & NYLI values & parentageFun at work

InputOutputExternalInternalAbsoluteRatios

GMPR RatingsTEC/TTR – TemplatesPrimary, Shared and ContributoryBalanced scorecardCore, Functional and Leadership Competencies

Part of top quartile newLife Insurance CompaniesNational PlayerBrand of FIRST choiceEmployer of ChoicePrincipal of Choice for AgentsKey Differentiators

Financial Strength & SecurityQuality of agentsFlexible ProductsService ExcellenceFair Terms of Business

41* Conservation Ratio = Renewal Premium for the current period / (First Year+Renewal Premium for the previous year)

Key Business Drivers Unit Year Ended Y-o-Y Growth Mar-09 Mar-08

a) Sales Value (Annualized first year premium) Rs. Crore 2,096 1,676 25%

b) Average case size Rs. 19,172 21,923 -13%

c) Case rate per agent per month No. 1.05 1.46 -28%

d) Number of agents No. 84,355 36,896 129%

e) Net agents added No. 47,459 11,848

f) Conservation ratio* % 82% 83%

g) Gross written premium income Rs. Crore

First year premium 1,594 1,326 20%

Renewal premium 2,014 1,117 80%

Single premium 249 272 -8%

Total 3,857 2,715 42%

h) Paid up Capital Rs. Crore 1,782 1,032 73%

i) Individual Policies in force No. 2,578,476 1,750,725 47%

j) Sum insured in force Rs. Crore 93,593 66,620 40%

MNYL – Key Highlights

42

MHC – Management Team

Dr. Pervez AhmedCEO and Managing Director

Dr. Ahmed has been an active participant in healthcare related fields especially development of standards of criticalcare medicine in New York. Since 1977 he has been involved in academic Medicine at SUNY, Downstate. He hasalso been involved in many healthcare activities in India dating back to 1980. Dr. Pervez Ahmed, MBBS from AFMC,Pune, has completed Residency in Internal Medicine and Fellow-ship in Cardiology in New York. He is Board certifiedin Internal and Cardiovascular disease and a Certified Medical Director.

Mr. Arvind KakarVice President Finance

Mr. Kakar is a Chartered Accountant with over 18 years of experience in service industries and having a high focus inthe areas of financial services and healthcare. He has been associated with the Max group since 2000.

Mr. Sanjay RaiDirector Marketing & Customer Management

Mr. Rai brings with him more than 28 years experience in Sales & Marketing in service and manufacturing industries.He has earlier worked with The Oberoi group and ITC Limited. He leads and manages various sales channels at MaxHealthcare and is also responsible for Branding, Customer Relationship Management and Direct marketing, PRfunction and for service excellence. He is an graduate in Economics from Mumbai University,

Mr. Surajit BanerjeeDirector Human Resource

Mr. Banerjee has over 23 years experience in Human resource and worked with reputed organizations like Spice Jet,Hindustan Lever, East India Hotels, Reckitt Bencksier Limited, Bharti Cellular etc. He is an post graduate in personnelmanagement and industrial relations from XLRI.

Dr. D. P. SaraswatRegional Director

Dr. Saraswat has rich and varied experience of 36 years including 22 years in the Indian Army where he held Lt. Col.rank. Thereafter he continued his career with Manipal Hospital as COO & Medical Director. He also held the positionof Head & Professor Dept. of Hospital Administration in Manipal University. He is M.B.B.S from S. N. Medical College,Agra and MHA from A F M C, Pune.

Dr. Dilpreet BrarRegional Director

Dr. Brar was associated with the Indraprastha Apollo Hospitals and Hero Honda group of companies prior to joiningMax Healthcare in 2002. She is responsible for business operations of Saket, Panchsheel and Gurgaon Hospitals. Dr.Brar is a graduate from Govt. Medical College, Patiala. She secured a post graduate diploma in hospital management,and completed a certificate course in Health Insurance from Indraprastha Apollo hospitals, New Delhi.

43

Padma Shri Dr. Rustom Phiroze Soonawala

MD, FRCS, FRCOG

Chairman, Obstetrics & Gynaecology

Eminent and Internationally renowned Obstetrician & Gynaecologist.

Former President of the Federation of Obstetricians and Gynaecologists

Dr. Praveen Chandra

MD, DM,FAPSIC, FACC, FSCAI, FESC

Director – Cardiac Cath Lab

Internationally Renowned Cardiologist.

First to use new devices like Rotarex,Kensey Nash DPD in the country.

Dr. S.K.S. Marya

M.S., DNB, Mch, FICS

Director – Max Institute of Orthopedics & Joint

Replacement

Renowned Joint Replacement Surgeon having 30 years experience.

Pioneered bilateral Hip and Knee Joint replacement.

Author and teacher par excellence.

Dr. Ajaya Nand Jha

MS, FRCS

Director – Max Institute of Neurosciences

Renowned Neurosurgeon with rich and varied experience including stints with

Manchester Royal Infirmary, P.D. Hinduja National Hospital, Indraprastha Apollo

Hospital.

First to use image guided Neurosurgery in the country.

First to use dedicated X-knife (Radiosurgery) and intra-operative MR with image

guidance for Brain Tumour Surgery.

Dr. Anurag Krishna

MS, MCh., FAMS

Director, Paediatrics and Paediatric Surgery

Over 20 years of experience in Paediatric surgery including complex congenital

malformations

Published over 50 scientific papers in leading national and international journals

Has served as Member of the Board of Management of Sir Ganga Ram Hospital.

MHC – Key Physicians

44

VISIONDeliver international class healthcare with a total service focus, by creating an institution committed to the highest standards of medical & service excellence, patient care, scientific knowledge, research and medical education.

MISSION

GOALS • Profitable without profiteering.• Seamless linkage between secondary and tertiary care.

KEY OBJECTIVES

STRATEGIES

WHAT – Medical USP’s ; Best in class ; Comprehensive care ; Convenience & accessibility ; Seamless service ; Patient records ; Consistent and customised care ; Service excellence ; Preventive health ; Caring place to work.

HOW – Train train train ; Partnership with Medical community ; Principal choice for physicians ; Never ending focus on medical and service excellence ; Build lasting customer relationships ; No franchising.

VALUES & BELIEFS OPERATING PRINCIPLESMETRICS &

STANDARDSPERFORMANCEMGMT PROCESS

• Create exceptional standards of Medical & Service Excellence• Care provider of FIRST CHOICE• Principal Choice for Physicians• Ethical Practices • Create International Centre of Excellence for select Super Specialties.• Safety – Patient, Customer, Staff

• Competence rating• Potential analysis• PSC model• Balanced scorecard• Performance / Risk linked

reward.

• Caring • Excellence• Integrity• - Personal• - Professional • Accountability• Openness/Transparency• Teamwork• Win-win partnerships

• Courtesy & Caring always• Customer comes first• Do it right first time• International image standards• Direct & open communications • Create trust• Compliance• Fun at work• Reward & Recognition

• JCIA Accreditation • ISO 9001 : 2000• Integrated Management System• Credentialing / Grant of privileges• Employee productivity• Employee Engagement survey• Service Dashboard - Sparsh• NABH/NABL Accreditation• Adverse event Measurement.

INITIATIVES• WHAT- HOW - WHEN - COST - LINKAGE• Shared responsibility with single accountability.• Unique approach through: - International benchmarking. - Walk the Talk - IT Capability- Medical – Management Alignment. - Rehearse rehearse - Cost Efficiency- Train train train. - Mystery customers - Attrition Management

MHC – Vision / MissionBuild TrustPASSIONKey Differentiators

Focused NCR centric delivery – for operational excellenceLeadership in 5 super-specialties in tertiary care-‘Star’ physicians supported by a group of high quality physiciansEthicsMemorable brand experience- ‘Star’ and quality physicians- Infrastructure and equipment- No surprises – cost of care, pricing, medication- Signage- Look – feel – smell - touchHigh quality nursing and paramedic care supported by nursing and paramedic collegeTechnology and IT

Key Public MessagesMedical ExcellenceService Excellence – Total ExperienceIn your community - near youHigh-end tertiary care in Private

sectorComprehensivenessReferral system – National &

InternationalValue for moneyCorporate Social Responsibility

45

Express Healthcare Excellence Awards (2007 – 08)

MHC – Accreditations and Awards

“Innovative Marketing Practices”

“Best Managed Healthcare Program (Health Insurance/TPA)”

First in North India to get NABH for MHVI & MSSH

ISO 14001:2004 at Pitampura

ISO 9001:2008 Recertification atMax Heart & Vascular Institute,Noida, Pitampura, PanchsheelPark & Home Office

46

Max Healthcare (MHC)

Key Business Drivers UnitYear Ended

Growth (%)Mar-09 Mar-08a) Revenue Rs. Crore

Inpatient Revenue 329.0 301.5 9%Outpatient Revenue 93.6 71.0 32%Total 422.6 372.5 13%

b) ProfitabilityContribution Margin Rs. Crore 238.9 197.7 21%Contribution (%) % 56.5% 53.1%EBITDA Rs. Crore 28.7 19.6 46%EBITDA (%) % 6.8% 5.3%Cash Profit Rs. Crore 1.0 (11.8) 108%

c) Patient Transactions No.Number of Procedures- Cardiac Care 7,437 7,648 -3%

- Orthopaedics 2,153 2,004 7%- Neurosciences 874 657 33%- Obstetrics & Gynaecology 4,861 4,171 17%- Others 9,669 8,214 18%Medical Admissions 26,109 23,838 10%Outpatient Registrations 1,899,880 1,592,804 19%

d) Average Operational Beds No. 712 662 8%e) Average Occupancy % 65.1% 65.8%f) Average Length of Stay No. 3.3 3.4 g) Average Revenue per Occupied Bed Day Rs. 19,433 18,914 3%

Note: The results presented above are for Max Healthcare’s network of hospital

47

MAX HEART & VASCULAR INSTITUTE(December 2004)n 200 patient bedsn 3 OTs, 2 Cardiac Catheterization Labsn Post Surgery Critical Care Unitn High Dependency Unitn Apex and Advanced Coronary Caren Exclusive well equipped ‘Observation Bay’ and

‘Post Cath. Recovery’n Nuclear Diagnostic Services with Variable Angle

Dual Head Gamma Cameran Centralized Emergency Command with

Advanced Cardiac Life Support Ambulances andAir Evacuation Service

n High-end General Surgery

MAX SUPER SPECIALITY HOSPITAL(May 2006)n 191 beds (including 63 critical care beds)n 7 OTs, 20 Consult Chambersn Tower Specialties – Orthopaedics, Neuro

Sciences, Obstetrics & Gynaecology, Paediatricsand Aesthetic & Reconstructive Surgery

n Brain Suite (first in Asia) and Intra Operative MRIn DSA Lab (for Neuro Sciences)n Emergency Servicesn High end Radiology facilities with 64 slice Cardiac

CT

MHC Tertiary Care Facility, Saket [South Delhi]

48

PITAMPURA(February 2002)(North Delhi)

90 inpatient beds2 OTsLithotripsyMother and child careNon-invasive cardiologyPlastic and reconstructive surgeryPhysiotherapyFull range diagnosticsPHP, OPD and Dentistry

PATPARGANJ(May 2005)(East Delhi)

154 inpatient beds3 OTsMother and child careOrthopaedicsGeneral surgeryCritical care including dialysisNon-invasive cardiology (incl. cardiac catheterization lab)ENT, ophthalmologyOther allied specialties

MHC Secondary Care Facility [ Delhi ]

49

MHC Secondary Care Facility [ Suburb of Delhi ]

NOIDA(August 2002)

33 inpatient beds2 OTsMother and child careNon-invasive cardiologyLaparoscopic surgeryOrthopaedicsENT, ophthalmologyUrology and nephrologyFull range diagnosticsPHP, OPD and Dentistry

GURGAON(July 2007)

102 inpatient beds 3 OTsOphthalmology (anterior and posterior)Woman and child (including infertility)Medical & surgical intensive careOrthopaedicsNephrology and urologyAesthetic and reconstructive surgeriesGeneral and minimally invasive surgeriesPHP and OPD

50

MHC Speciality Centres – Panchsheel [South Delhi]

OPTHALMOLOGY AND DENTAL CARE(November 2005)

Lasik, OPD and diagnosticsDental – 3 chambersSupport services and offices

SPECIALIST CONSULTS AND HIGH-END DIAGNOSTICS (August 2006)

GP and specialist consultsDiagnosticsNeurology (EEG and EMG)Preventive health and chronic carePhysiotherapyMinor procedures and emergenciesIVF

51

MSP – Performance Snapshot

Key Business Drivers UnitYear Ended Growth

(%)Mar-09 Mar-08

a) Sales Quantity – BOPP Tons 28,503 23,929 19%

b) Revenue Rs. Crore 370.4 306.0 21%

c) Profitability:

Contribution Margin* Rs. Crore 136.8 119.9 14%

% 36.9% 39.2%

EBITDA Rs. Crore 51.4 49.6 4%

% 13.9% 16.2%

PBT Rs. Crore 24.8 24.5 1%

% 6.7% 8.0%

52

DisclaimerThis presentation has been prepared by Max India Limited (the “Company”). No representation or warranty, express or implied, is made and no

reliance should be placed on the accuracy, fairness or completeness of the information presented or contained in the presentation. The past

performance is not indicative of future results. Neither the Company nor any of its affiliates, advisers or representatives accepts liability

whatsoever for any loss howsoever arising from any information presented or contained in the presentation. The information presented or

contained in these materials is subject to change without notice and its accuracy is not guaranteed.

The presentation may also contain statements that are forward looking. These statements are based on current expectations and assumptions

that are subject to risks and uncertainties. Actual results could differ materially from our expectations and assumptions. We do not undertake

any responsibility to update any forward looking statements nor should this be constituted as a guidance of future performance.

This presentation does not constitute a prospectus or offering memorandum or an offer to acquire any securities and is not intended to provide

the basis for evaluation of the securities. Neither this presentation nor any other documentation or information (or any part thereof) delivered or

supplied under or in relation to the securities shall be deemed to constitute an offer of or an invitation.

No person is authorised to give any information or to make any representation not contained in and not consistent with this presentation and, if

given or made, such information or representation must not be relied upon as having been authorised by or on behalf of the Company any of

its affiliates, advisers or representatives.

The Company’s Securities have not been and are not intended to be registered under the United States Securities Act of 1993, as amended (the

“Securities Act”), or any State Securities Law and unless so registered may not be offered or sold within the United States or to, or for the

benefit of, U.S. Persons (as defined in Regulations S under the Securities Act) except pursuant to an exemption from, or in a transaction not

subject to, the registration requirements of the Securities Act and the applicable State Securities Laws.

This presentation is highly confidential, and is solely for your information and may not be copied, reproduced or distributed to any other

person in any manner. Unauthorized copying, reproduction, or distribution of any of the presentation into the U.S. or to any “U.S. persons” (as

defined in Regulation S under the Securities Act) or other third parties ( including journalists) could prejudice, any potential future offering of

shares by the Company. You agree to keep the contents of this presentation and these materials confidential.

53

54

55

56

MAX INDIA LTD.Max House, Okhla, New Delhi – 110 020

Phone: +91 11 26933601-10 Fax: +91 11 26933619Website: www.maxindia.com